Hepatitis C ; prevention & control ; therapy ; Humans

China ; Hepatitis C ; prevention & control ; therapy ; Humans

Hepatitis C ; genetics ; prevention & control ; therapy ; Humans ; MicroRNAs

In the past 20 years, Chinese Medical Association had issued several versions of hepatitis C prevention and treatment guidelines. In the latest guidelines published in 2022, the Chinese Society of Hepatology and the Society of Infectious Diseases for the Chinese Medical Association organized experts to update their recommendations for hepatitis C screening and treatment. The updated key points on prevention, diagnosis, and treatment proposed in the guidelines are now interpreted, aiming to provide reference for more effective clinical application of the guidelines.
Humans ; Hepacivirus ; Hepatitis C/prevention & control* ; Mass Screening ; Asian People

Animals ; Hepacivirus ; genetics ; Hepatitis C ; immunology ; prevention & control ; therapy ; virology ; Humans ; Mutation ; Viral Hepatitis Vaccines ; immunology

Hepatitis C ; etiology ; prevention & control ; surgery ; Humans ; Liver Transplantation ; Secondary Prevention

Australia ; HIV Infections ; prevention & control ; transmission ; Hepatitis B ; prevention & control ; transmission ; Hepatitis C ; prevention & control ; transmission ; Humans ; Infectious Disease Transmission, Patient-to-Professional ; prevention & control ; Occupational Exposure ; Risk Assessment

OBJECTIVETo understand the epidemiological features of viral hepatitis, and provide scientific evidence for developing strategies for prevention and control.

METHODSThrough descriptive epidemiological methodology, the epidemiological characteristics of 1121 viral hepatitis cases in Chongwen District (1997-2006) were studied. chi2-test was used in ratio comparison.

RESULTSThere were 1121 viral hepatitis cases occurring in the past decade, and the incidence rate was declining by year with the average of 27.10/ 100,000. Of which, the incidence rate of viral hepatitis B was the highest (13.90/ 100,000), viral hepatitis C (1.38/100,000) was the lowest. The proportion of viral hepatitis B was the highest (575, 51.29%) and viral hepatitis C (57, 5.08%) was the lowest. The incidence of viral hepatitis A, B and no-typing was declining year by year, while viral hepatitis C and E was climbing. Most viral hepatitis A and E cases occurred in Spring and Winter, and the difference of incidence rate between male and female was observed (chi2 = 188.39, P < 0.001). The findings also showed that viral hepatitis might occur in all kind of occupation, but most were workers (306, 27.3%) and officers (209, 18.64%). For the age distribution, 20 -49 years old group took the majority (749, 66.82%); and for the transmission route, blood transfusion (7.64/ 100,000) was significantly higher than fecal-oral route (3.02/ 100,000) (chi2 = 5.09, P < 0.01).

CONCLUSIONIt is necessary to raise and increase the public awareness for viral hepatitis prevention and control, and enhance immunization. Moreover, effective measures should be taken to the safety of blood and blood products, and to prevent nosocomial infection.

Adolescent ; Adult ; China ; epidemiology ; Female ; Hepatitis A ; epidemiology ; prevention & control ; Hepatitis B ; epidemiology ; prevention & control ; Hepatitis C ; epidemiology ; prevention & control ; Hepatitis, Viral, Human ; epidemiology ; prevention & control ; Humans ; Incidence ; Male ; Middle Aged

China ; Hepatitis B ; prevention & control ; therapy ; Hepatitis C ; prevention & control ; therapy ; Hepatitis, Viral, Human ; therapy ; Humans ; Multicenter Studies as Topic ; Randomized Controlled Trials as Topic

OBJECTIVETo observe the immunogenicity of combined hepatitis A and B vaccine (HAB).

METHODSThe combined HAB vaccine was prepared and different concentrations of HAB were administered on mice in week 0, 4 and 24, and then we tested the antibodies to both hepatitis A virus and B virus. After the first injection, we tested the hepatitis A antigen-induced and hepatitis B surface antigen-induced stimulation indices in spleen monocyte as well as changes of CD4+ and CD8+ cell numbers.

RESULTSThe serum antibody positive rates were 100% in all three groups, and the antibody induced by HAB vaccine were earlier than by monovalent vaccine. The hepatitis A antibody and hepatitis B surface antibody titers after the combined vaccine inoculation were not significantly higher than those after the monovalent vaccine inoculation. On the other hand, after the first injection of the combined vaccine, the hepatitis A antigen-induced and hepatitis B surface antigen-induced stimulation indices in spleen monocyte were detected. The numbers of CD4+ and CD8+ cells increased.

CONCLUSIONSHAB vaccine has reliable immunogenicity.

Animals ; CD4-CD8 Ratio ; Hepatitis A ; prevention & control ; Hepatitis A Antibodies ; blood ; Hepatitis A Vaccines ; immunology ; Hepatitis B ; prevention & control ; Hepatitis B Antibodies ; blood ; Hepatitis B Vaccines ; immunology ; Leukocytes, Mononuclear ; immunology ; Mice ; Mice, Inbred BALB C ; Random Allocation ; Vaccination ; Vaccines, Combined ; immunology